Global Anti-VEGF Therapeutic Market Research Report 2024, Forecast to 2032
Report Overview
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
The global Anti-VEGF Therapeutic market size was estimated at USD 833 million in 2023 and is projected to reach USD 1505.87 million by 2032, exhibiting a CAGR of 6.80% during the forecast period.
North America Anti-VEGF Therapeutic market size was estimated at USD 243.10 million in 2023, at a CAGR of 5.83% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Anti-VEGF Therapeutic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Anti-VEGF Therapeutic Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Anti-VEGF Therapeutic market in any manner.
Global Anti-VEGF Therapeutic Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Market Segmentation (by Type)
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others
Market Segmentation (by Application)
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Anti-VEGF Therapeutic Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Anti-VEGF Therapeutic, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF therapy or medication, is the use of medications that block vascular endothelial growth factor.
The global Anti-VEGF Therapeutic market size was estimated at USD 833 million in 2023 and is projected to reach USD 1505.87 million by 2032, exhibiting a CAGR of 6.80% during the forecast period.
North America Anti-VEGF Therapeutic market size was estimated at USD 243.10 million in 2023, at a CAGR of 5.83% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Anti-VEGF Therapeutic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Anti-VEGF Therapeutic Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Anti-VEGF Therapeutic market in any manner.
Global Anti-VEGF Therapeutic Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Regeneron Pharmaceuticals
Bayer
Novartis
Roche
Biogen
Pfizer
Coherus BioSciences
Amgen
Bausch Health Companies
Viatris
Market Segmentation (by Type)
Aflibercept (Eylea)
Ranibizumab (Lucentis)
Brolucizumab (Beovu)
Others
Market Segmentation (by Application)
Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Anti-VEGF Therapeutic Market
- Overview of the regional outlook of the Anti-VEGF Therapeutic Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Anti-VEGF Therapeutic Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Anti-VEGF Therapeutic, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Anti-VEGF Therapeutic
1.2 Key Market Segments
1.2.1 Anti-VEGF Therapeutic Segment by Type
1.2.2 Anti-VEGF Therapeutic Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTI-VEGF THERAPEUTIC MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Anti-VEGF Therapeutic Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Anti-VEGF Therapeutic Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTI-VEGF THERAPEUTIC MARKET COMPETITIVE LANDSCAPE
3.1 Global Anti-VEGF Therapeutic Sales by Manufacturers (2019-2024)
3.2 Global Anti-VEGF Therapeutic Revenue Market Share by Manufacturers (2019-2024)
3.3 Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Anti-VEGF Therapeutic Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Anti-VEGF Therapeutic Sales Sites, Area Served, Product Type
3.6 Anti-VEGF Therapeutic Market Competitive Situation and Trends
3.6.1 Anti-VEGF Therapeutic Market Concentration Rate
3.6.2 Global 5 and 10 Largest Anti-VEGF Therapeutic Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTI-VEGF THERAPEUTIC INDUSTRY CHAIN ANALYSIS
4.1 Anti-VEGF Therapeutic Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTI-VEGF THERAPEUTIC MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTI-VEGF THERAPEUTIC MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Anti-VEGF Therapeutic Sales Market Share by Type (2019-2024)
6.3 Global Anti-VEGF Therapeutic Market Size Market Share by Type (2019-2024)
6.4 Global Anti-VEGF Therapeutic Price by Type (2019-2024)
7 ANTI-VEGF THERAPEUTIC MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Anti-VEGF Therapeutic Market Sales by Application (2019-2024)
7.3 Global Anti-VEGF Therapeutic Market Size (M USD) by Application (2019-2024)
7.4 Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
8 ANTI-VEGF THERAPEUTIC MARKET CONSUMPTION BY REGION
8.1 Global Anti-VEGF Therapeutic Sales by Region
8.1.1 Global Anti-VEGF Therapeutic Sales by Region
8.1.2 Global Anti-VEGF Therapeutic Sales Market Share by Region
8.2 North America
8.2.1 North America Anti-VEGF Therapeutic Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Anti-VEGF Therapeutic Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Anti-VEGF Therapeutic Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Anti-VEGF Therapeutic Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Anti-VEGF Therapeutic Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTI-VEGF THERAPEUTIC MARKET PRODUCTION BY REGION
9.1 Global Production of Anti-VEGF Therapeutic by Region (2019-2024)
9.2 Global Anti-VEGF Therapeutic Revenue Market Share by Region (2019-2024)
9.3 Global Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Anti-VEGF Therapeutic Production
9.4.1 North America Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.4.2 North America Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Anti-VEGF Therapeutic Production
9.5.1 Europe Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.5.2 Europe Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Anti-VEGF Therapeutic Production (2019-2024)
9.6.1 Japan Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.6.2 Japan Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Anti-VEGF Therapeutic Production (2019-2024)
9.7.1 China Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.7.2 China Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Regeneron Pharmaceuticals
10.1.1 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Basic Information
10.1.2 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Overview
10.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Market Performance
10.1.4 Regeneron Pharmaceuticals Business Overview
10.1.5 Regeneron Pharmaceuticals Anti-VEGF Therapeutic SWOT Analysis
10.1.6 Regeneron Pharmaceuticals Recent Developments
10.2 Bayer
10.2.1 Bayer Anti-VEGF Therapeutic Basic Information
10.2.2 Bayer Anti-VEGF Therapeutic Product Overview
10.2.3 Bayer Anti-VEGF Therapeutic Product Market Performance
10.2.4 Bayer Business Overview
10.2.5 Bayer Anti-VEGF Therapeutic SWOT Analysis
10.2.6 Bayer Recent Developments
10.3 Novartis
10.3.1 Novartis Anti-VEGF Therapeutic Basic Information
10.3.2 Novartis Anti-VEGF Therapeutic Product Overview
10.3.3 Novartis Anti-VEGF Therapeutic Product Market Performance
10.3.4 Novartis Anti-VEGF Therapeutic SWOT Analysis
10.3.5 Novartis Business Overview
10.3.6 Novartis Recent Developments
10.4 Roche
10.4.1 Roche Anti-VEGF Therapeutic Basic Information
10.4.2 Roche Anti-VEGF Therapeutic Product Overview
10.4.3 Roche Anti-VEGF Therapeutic Product Market Performance
10.4.4 Roche Business Overview
10.4.5 Roche Recent Developments
10.5 Biogen
10.5.1 Biogen Anti-VEGF Therapeutic Basic Information
10.5.2 Biogen Anti-VEGF Therapeutic Product Overview
10.5.3 Biogen Anti-VEGF Therapeutic Product Market Performance
10.5.4 Biogen Business Overview
10.5.5 Biogen Recent Developments
10.6 Pfizer
10.6.1 Pfizer Anti-VEGF Therapeutic Basic Information
10.6.2 Pfizer Anti-VEGF Therapeutic Product Overview
10.6.3 Pfizer Anti-VEGF Therapeutic Product Market Performance
10.6.4 Pfizer Business Overview
10.6.5 Pfizer Recent Developments
10.7 Coherus BioSciences
10.7.1 Coherus BioSciences Anti-VEGF Therapeutic Basic Information
10.7.2 Coherus BioSciences Anti-VEGF Therapeutic Product Overview
10.7.3 Coherus BioSciences Anti-VEGF Therapeutic Product Market Performance
10.7.4 Coherus BioSciences Business Overview
10.7.5 Coherus BioSciences Recent Developments
10.8 Amgen
10.8.1 Amgen Anti-VEGF Therapeutic Basic Information
10.8.2 Amgen Anti-VEGF Therapeutic Product Overview
10.8.3 Amgen Anti-VEGF Therapeutic Product Market Performance
10.8.4 Amgen Business Overview
10.8.5 Amgen Recent Developments
10.9 Bausch Health Companies
10.9.1 Bausch Health Companies Anti-VEGF Therapeutic Basic Information
10.9.2 Bausch Health Companies Anti-VEGF Therapeutic Product Overview
10.9.3 Bausch Health Companies Anti-VEGF Therapeutic Product Market Performance
10.9.4 Bausch Health Companies Business Overview
10.9.5 Bausch Health Companies Recent Developments
10.10 Viatris
10.10.1 Viatris Anti-VEGF Therapeutic Basic Information
10.10.2 Viatris Anti-VEGF Therapeutic Product Overview
10.10.3 Viatris Anti-VEGF Therapeutic Product Market Performance
10.10.4 Viatris Business Overview
10.10.5 Viatris Recent Developments
11 ANTI-VEGF THERAPEUTIC MARKET FORECAST BY REGION
11.1 Global Anti-VEGF Therapeutic Market Size Forecast
11.2 Global Anti-VEGF Therapeutic Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Anti-VEGF Therapeutic Market Size Forecast by Country
11.2.3 Asia Pacific Anti-VEGF Therapeutic Market Size Forecast by Region
11.2.4 South America Anti-VEGF Therapeutic Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Anti-VEGF Therapeutic by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Anti-VEGF Therapeutic Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Anti-VEGF Therapeutic by Type (2025-2032)
12.1.2 Global Anti-VEGF Therapeutic Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Anti-VEGF Therapeutic by Type (2025-2032)
12.2 Global Anti-VEGF Therapeutic Market Forecast by Application (2025-2032)
12.2.1 Global Anti-VEGF Therapeutic Sales (K MT) Forecast by Application
12.2.2 Global Anti-VEGF Therapeutic Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Anti-VEGF Therapeutic
1.2 Key Market Segments
1.2.1 Anti-VEGF Therapeutic Segment by Type
1.2.2 Anti-VEGF Therapeutic Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTI-VEGF THERAPEUTIC MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Anti-VEGF Therapeutic Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Anti-VEGF Therapeutic Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTI-VEGF THERAPEUTIC MARKET COMPETITIVE LANDSCAPE
3.1 Global Anti-VEGF Therapeutic Sales by Manufacturers (2019-2024)
3.2 Global Anti-VEGF Therapeutic Revenue Market Share by Manufacturers (2019-2024)
3.3 Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Anti-VEGF Therapeutic Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Anti-VEGF Therapeutic Sales Sites, Area Served, Product Type
3.6 Anti-VEGF Therapeutic Market Competitive Situation and Trends
3.6.1 Anti-VEGF Therapeutic Market Concentration Rate
3.6.2 Global 5 and 10 Largest Anti-VEGF Therapeutic Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTI-VEGF THERAPEUTIC INDUSTRY CHAIN ANALYSIS
4.1 Anti-VEGF Therapeutic Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTI-VEGF THERAPEUTIC MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTI-VEGF THERAPEUTIC MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Anti-VEGF Therapeutic Sales Market Share by Type (2019-2024)
6.3 Global Anti-VEGF Therapeutic Market Size Market Share by Type (2019-2024)
6.4 Global Anti-VEGF Therapeutic Price by Type (2019-2024)
7 ANTI-VEGF THERAPEUTIC MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Anti-VEGF Therapeutic Market Sales by Application (2019-2024)
7.3 Global Anti-VEGF Therapeutic Market Size (M USD) by Application (2019-2024)
7.4 Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
8 ANTI-VEGF THERAPEUTIC MARKET CONSUMPTION BY REGION
8.1 Global Anti-VEGF Therapeutic Sales by Region
8.1.1 Global Anti-VEGF Therapeutic Sales by Region
8.1.2 Global Anti-VEGF Therapeutic Sales Market Share by Region
8.2 North America
8.2.1 North America Anti-VEGF Therapeutic Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Anti-VEGF Therapeutic Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Anti-VEGF Therapeutic Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Anti-VEGF Therapeutic Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Anti-VEGF Therapeutic Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTI-VEGF THERAPEUTIC MARKET PRODUCTION BY REGION
9.1 Global Production of Anti-VEGF Therapeutic by Region (2019-2024)
9.2 Global Anti-VEGF Therapeutic Revenue Market Share by Region (2019-2024)
9.3 Global Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Anti-VEGF Therapeutic Production
9.4.1 North America Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.4.2 North America Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Anti-VEGF Therapeutic Production
9.5.1 Europe Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.5.2 Europe Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Anti-VEGF Therapeutic Production (2019-2024)
9.6.1 Japan Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.6.2 Japan Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Anti-VEGF Therapeutic Production (2019-2024)
9.7.1 China Anti-VEGF Therapeutic Production Growth Rate (2019-2024)
9.7.2 China Anti-VEGF Therapeutic Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Regeneron Pharmaceuticals
10.1.1 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Basic Information
10.1.2 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Overview
10.1.3 Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Market Performance
10.1.4 Regeneron Pharmaceuticals Business Overview
10.1.5 Regeneron Pharmaceuticals Anti-VEGF Therapeutic SWOT Analysis
10.1.6 Regeneron Pharmaceuticals Recent Developments
10.2 Bayer
10.2.1 Bayer Anti-VEGF Therapeutic Basic Information
10.2.2 Bayer Anti-VEGF Therapeutic Product Overview
10.2.3 Bayer Anti-VEGF Therapeutic Product Market Performance
10.2.4 Bayer Business Overview
10.2.5 Bayer Anti-VEGF Therapeutic SWOT Analysis
10.2.6 Bayer Recent Developments
10.3 Novartis
10.3.1 Novartis Anti-VEGF Therapeutic Basic Information
10.3.2 Novartis Anti-VEGF Therapeutic Product Overview
10.3.3 Novartis Anti-VEGF Therapeutic Product Market Performance
10.3.4 Novartis Anti-VEGF Therapeutic SWOT Analysis
10.3.5 Novartis Business Overview
10.3.6 Novartis Recent Developments
10.4 Roche
10.4.1 Roche Anti-VEGF Therapeutic Basic Information
10.4.2 Roche Anti-VEGF Therapeutic Product Overview
10.4.3 Roche Anti-VEGF Therapeutic Product Market Performance
10.4.4 Roche Business Overview
10.4.5 Roche Recent Developments
10.5 Biogen
10.5.1 Biogen Anti-VEGF Therapeutic Basic Information
10.5.2 Biogen Anti-VEGF Therapeutic Product Overview
10.5.3 Biogen Anti-VEGF Therapeutic Product Market Performance
10.5.4 Biogen Business Overview
10.5.5 Biogen Recent Developments
10.6 Pfizer
10.6.1 Pfizer Anti-VEGF Therapeutic Basic Information
10.6.2 Pfizer Anti-VEGF Therapeutic Product Overview
10.6.3 Pfizer Anti-VEGF Therapeutic Product Market Performance
10.6.4 Pfizer Business Overview
10.6.5 Pfizer Recent Developments
10.7 Coherus BioSciences
10.7.1 Coherus BioSciences Anti-VEGF Therapeutic Basic Information
10.7.2 Coherus BioSciences Anti-VEGF Therapeutic Product Overview
10.7.3 Coherus BioSciences Anti-VEGF Therapeutic Product Market Performance
10.7.4 Coherus BioSciences Business Overview
10.7.5 Coherus BioSciences Recent Developments
10.8 Amgen
10.8.1 Amgen Anti-VEGF Therapeutic Basic Information
10.8.2 Amgen Anti-VEGF Therapeutic Product Overview
10.8.3 Amgen Anti-VEGF Therapeutic Product Market Performance
10.8.4 Amgen Business Overview
10.8.5 Amgen Recent Developments
10.9 Bausch Health Companies
10.9.1 Bausch Health Companies Anti-VEGF Therapeutic Basic Information
10.9.2 Bausch Health Companies Anti-VEGF Therapeutic Product Overview
10.9.3 Bausch Health Companies Anti-VEGF Therapeutic Product Market Performance
10.9.4 Bausch Health Companies Business Overview
10.9.5 Bausch Health Companies Recent Developments
10.10 Viatris
10.10.1 Viatris Anti-VEGF Therapeutic Basic Information
10.10.2 Viatris Anti-VEGF Therapeutic Product Overview
10.10.3 Viatris Anti-VEGF Therapeutic Product Market Performance
10.10.4 Viatris Business Overview
10.10.5 Viatris Recent Developments
11 ANTI-VEGF THERAPEUTIC MARKET FORECAST BY REGION
11.1 Global Anti-VEGF Therapeutic Market Size Forecast
11.2 Global Anti-VEGF Therapeutic Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Anti-VEGF Therapeutic Market Size Forecast by Country
11.2.3 Asia Pacific Anti-VEGF Therapeutic Market Size Forecast by Region
11.2.4 South America Anti-VEGF Therapeutic Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Anti-VEGF Therapeutic by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Anti-VEGF Therapeutic Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Anti-VEGF Therapeutic by Type (2025-2032)
12.1.2 Global Anti-VEGF Therapeutic Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Anti-VEGF Therapeutic by Type (2025-2032)
12.2 Global Anti-VEGF Therapeutic Market Forecast by Application (2025-2032)
12.2.1 Global Anti-VEGF Therapeutic Sales (K MT) Forecast by Application
12.2.2 Global Anti-VEGF Therapeutic Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Anti-VEGF Therapeutic Market Size Comparison by Region (M USD)
Table 5. Global Anti-VEGF Therapeutic Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Anti-VEGF Therapeutic Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapeutic as of 2022)
Table 10. Global Market Anti-VEGF Therapeutic Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Anti-VEGF Therapeutic Sales Sites and Area Served
Table 12. Manufacturers Anti-VEGF Therapeutic Product Type
Table 13. Global Anti-VEGF Therapeutic Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Anti-VEGF Therapeutic
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Anti-VEGF Therapeutic Market Challenges
Table 22. Global Anti-VEGF Therapeutic Sales by Type (K MT)
Table 23. Global Anti-VEGF Therapeutic Market Size by Type (M USD)
Table 24. Global Anti-VEGF Therapeutic Sales (K MT) by Type (2019-2024)
Table 25. Global Anti-VEGF Therapeutic Sales Market Share by Type (2019-2024)
Table 26. Global Anti-VEGF Therapeutic Market Size (M USD) by Type (2019-2024)
Table 27. Global Anti-VEGF Therapeutic Market Size Share by Type (2019-2024)
Table 28. Global Anti-VEGF Therapeutic Price (USD/MT) by Type (2019-2024)
Table 29. Global Anti-VEGF Therapeutic Sales (K MT) by Application
Table 30. Global Anti-VEGF Therapeutic Market Size by Application
Table 31. Global Anti-VEGF Therapeutic Sales by Application (2019-2024) & (K MT)
Table 32. Global Anti-VEGF Therapeutic Sales Market Share by Application (2019-2024)
Table 33. Global Anti-VEGF Therapeutic Sales by Application (2019-2024) & (M USD)
Table 34. Global Anti-VEGF Therapeutic Market Share by Application (2019-2024)
Table 35. Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
Table 36. Global Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 37. Global Anti-VEGF Therapeutic Sales Market Share by Region (2019-2024)
Table 38. North America Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 39. Europe Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 41. South America Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 43. Global Anti-VEGF Therapeutic Production (K MT) by Region (2019-2024)
Table 44. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2019-2024)
Table 46. Global Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Basic Information
Table 52. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Overview
Table 53. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Regeneron Pharmaceuticals Business Overview
Table 55. Regeneron Pharmaceuticals Anti-VEGF Therapeutic SWOT Analysis
Table 56. Regeneron Pharmaceuticals Recent Developments
Table 57. Bayer Anti-VEGF Therapeutic Basic Information
Table 58. Bayer Anti-VEGF Therapeutic Product Overview
Table 59. Bayer Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Bayer Business Overview
Table 61. Bayer Anti-VEGF Therapeutic SWOT Analysis
Table 62. Bayer Recent Developments
Table 63. Novartis Anti-VEGF Therapeutic Basic Information
Table 64. Novartis Anti-VEGF Therapeutic Product Overview
Table 65. Novartis Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Novartis Anti-VEGF Therapeutic SWOT Analysis
Table 67. Novartis Business Overview
Table 68. Novartis Recent Developments
Table 69. Roche Anti-VEGF Therapeutic Basic Information
Table 70. Roche Anti-VEGF Therapeutic Product Overview
Table 71. Roche Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Roche Business Overview
Table 73. Roche Recent Developments
Table 74. Biogen Anti-VEGF Therapeutic Basic Information
Table 75. Biogen Anti-VEGF Therapeutic Product Overview
Table 76. Biogen Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Biogen Business Overview
Table 78. Biogen Recent Developments
Table 79. Pfizer Anti-VEGF Therapeutic Basic Information
Table 80. Pfizer Anti-VEGF Therapeutic Product Overview
Table 81. Pfizer Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Pfizer Business Overview
Table 83. Pfizer Recent Developments
Table 84. Coherus BioSciences Anti-VEGF Therapeutic Basic Information
Table 85. Coherus BioSciences Anti-VEGF Therapeutic Product Overview
Table 86. Coherus BioSciences Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Coherus BioSciences Business Overview
Table 88. Coherus BioSciences Recent Developments
Table 89. Amgen Anti-VEGF Therapeutic Basic Information
Table 90. Amgen Anti-VEGF Therapeutic Product Overview
Table 91. Amgen Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Amgen Business Overview
Table 93. Amgen Recent Developments
Table 94. Bausch Health Companies Anti-VEGF Therapeutic Basic Information
Table 95. Bausch Health Companies Anti-VEGF Therapeutic Product Overview
Table 96. Bausch Health Companies Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Bausch Health Companies Business Overview
Table 98. Bausch Health Companies Recent Developments
Table 99. Viatris Anti-VEGF Therapeutic Basic Information
Table 100. Viatris Anti-VEGF Therapeutic Product Overview
Table 101. Viatris Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Viatris Business Overview
Table 103. Viatris Recent Developments
Table 104. Global Anti-VEGF Therapeutic Sales Forecast by Region (2025-2032) & (K MT)
Table 105. Global Anti-VEGF Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)
Table 106. North America Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 107. North America Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 108. Europe Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 109. Europe Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 110. Asia Pacific Anti-VEGF Therapeutic Sales Forecast by Region (2025-2032) & (K MT)
Table 111. Asia Pacific Anti-VEGF Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)
Table 112. South America Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 113. South America Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 114. Middle East and Africa Anti-VEGF Therapeutic Consumption Forecast by Country (2025-2032) & (Units)
Table 115. Middle East and Africa Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 116. Global Anti-VEGF Therapeutic Sales Forecast by Type (2025-2032) & (K MT)
Table 117. Global Anti-VEGF Therapeutic Market Size Forecast by Type (2025-2032) & (M USD)
Table 118. Global Anti-VEGF Therapeutic Price Forecast by Type (2025-2032) & (USD/MT)
Table 119. Global Anti-VEGF Therapeutic Sales (K MT) Forecast by Application (2025-2032)
Table 120. Global Anti-VEGF Therapeutic Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Anti-VEGF Therapeutic Market Size Comparison by Region (M USD)
Table 5. Global Anti-VEGF Therapeutic Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Anti-VEGF Therapeutic Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Anti-VEGF Therapeutic Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapeutic as of 2022)
Table 10. Global Market Anti-VEGF Therapeutic Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Anti-VEGF Therapeutic Sales Sites and Area Served
Table 12. Manufacturers Anti-VEGF Therapeutic Product Type
Table 13. Global Anti-VEGF Therapeutic Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Anti-VEGF Therapeutic
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Anti-VEGF Therapeutic Market Challenges
Table 22. Global Anti-VEGF Therapeutic Sales by Type (K MT)
Table 23. Global Anti-VEGF Therapeutic Market Size by Type (M USD)
Table 24. Global Anti-VEGF Therapeutic Sales (K MT) by Type (2019-2024)
Table 25. Global Anti-VEGF Therapeutic Sales Market Share by Type (2019-2024)
Table 26. Global Anti-VEGF Therapeutic Market Size (M USD) by Type (2019-2024)
Table 27. Global Anti-VEGF Therapeutic Market Size Share by Type (2019-2024)
Table 28. Global Anti-VEGF Therapeutic Price (USD/MT) by Type (2019-2024)
Table 29. Global Anti-VEGF Therapeutic Sales (K MT) by Application
Table 30. Global Anti-VEGF Therapeutic Market Size by Application
Table 31. Global Anti-VEGF Therapeutic Sales by Application (2019-2024) & (K MT)
Table 32. Global Anti-VEGF Therapeutic Sales Market Share by Application (2019-2024)
Table 33. Global Anti-VEGF Therapeutic Sales by Application (2019-2024) & (M USD)
Table 34. Global Anti-VEGF Therapeutic Market Share by Application (2019-2024)
Table 35. Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
Table 36. Global Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 37. Global Anti-VEGF Therapeutic Sales Market Share by Region (2019-2024)
Table 38. North America Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 39. Europe Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 41. South America Anti-VEGF Therapeutic Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Anti-VEGF Therapeutic Sales by Region (2019-2024) & (K MT)
Table 43. Global Anti-VEGF Therapeutic Production (K MT) by Region (2019-2024)
Table 44. Global Anti-VEGF Therapeutic Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Anti-VEGF Therapeutic Revenue Market Share by Region (2019-2024)
Table 46. Global Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Anti-VEGF Therapeutic Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Basic Information
Table 52. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Product Overview
Table 53. Regeneron Pharmaceuticals Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Regeneron Pharmaceuticals Business Overview
Table 55. Regeneron Pharmaceuticals Anti-VEGF Therapeutic SWOT Analysis
Table 56. Regeneron Pharmaceuticals Recent Developments
Table 57. Bayer Anti-VEGF Therapeutic Basic Information
Table 58. Bayer Anti-VEGF Therapeutic Product Overview
Table 59. Bayer Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Bayer Business Overview
Table 61. Bayer Anti-VEGF Therapeutic SWOT Analysis
Table 62. Bayer Recent Developments
Table 63. Novartis Anti-VEGF Therapeutic Basic Information
Table 64. Novartis Anti-VEGF Therapeutic Product Overview
Table 65. Novartis Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Novartis Anti-VEGF Therapeutic SWOT Analysis
Table 67. Novartis Business Overview
Table 68. Novartis Recent Developments
Table 69. Roche Anti-VEGF Therapeutic Basic Information
Table 70. Roche Anti-VEGF Therapeutic Product Overview
Table 71. Roche Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Roche Business Overview
Table 73. Roche Recent Developments
Table 74. Biogen Anti-VEGF Therapeutic Basic Information
Table 75. Biogen Anti-VEGF Therapeutic Product Overview
Table 76. Biogen Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Biogen Business Overview
Table 78. Biogen Recent Developments
Table 79. Pfizer Anti-VEGF Therapeutic Basic Information
Table 80. Pfizer Anti-VEGF Therapeutic Product Overview
Table 81. Pfizer Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Pfizer Business Overview
Table 83. Pfizer Recent Developments
Table 84. Coherus BioSciences Anti-VEGF Therapeutic Basic Information
Table 85. Coherus BioSciences Anti-VEGF Therapeutic Product Overview
Table 86. Coherus BioSciences Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Coherus BioSciences Business Overview
Table 88. Coherus BioSciences Recent Developments
Table 89. Amgen Anti-VEGF Therapeutic Basic Information
Table 90. Amgen Anti-VEGF Therapeutic Product Overview
Table 91. Amgen Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Amgen Business Overview
Table 93. Amgen Recent Developments
Table 94. Bausch Health Companies Anti-VEGF Therapeutic Basic Information
Table 95. Bausch Health Companies Anti-VEGF Therapeutic Product Overview
Table 96. Bausch Health Companies Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Bausch Health Companies Business Overview
Table 98. Bausch Health Companies Recent Developments
Table 99. Viatris Anti-VEGF Therapeutic Basic Information
Table 100. Viatris Anti-VEGF Therapeutic Product Overview
Table 101. Viatris Anti-VEGF Therapeutic Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Viatris Business Overview
Table 103. Viatris Recent Developments
Table 104. Global Anti-VEGF Therapeutic Sales Forecast by Region (2025-2032) & (K MT)
Table 105. Global Anti-VEGF Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)
Table 106. North America Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 107. North America Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 108. Europe Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 109. Europe Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 110. Asia Pacific Anti-VEGF Therapeutic Sales Forecast by Region (2025-2032) & (K MT)
Table 111. Asia Pacific Anti-VEGF Therapeutic Market Size Forecast by Region (2025-2032) & (M USD)
Table 112. South America Anti-VEGF Therapeutic Sales Forecast by Country (2025-2032) & (K MT)
Table 113. South America Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 114. Middle East and Africa Anti-VEGF Therapeutic Consumption Forecast by Country (2025-2032) & (Units)
Table 115. Middle East and Africa Anti-VEGF Therapeutic Market Size Forecast by Country (2025-2032) & (M USD)
Table 116. Global Anti-VEGF Therapeutic Sales Forecast by Type (2025-2032) & (K MT)
Table 117. Global Anti-VEGF Therapeutic Market Size Forecast by Type (2025-2032) & (M USD)
Table 118. Global Anti-VEGF Therapeutic Price Forecast by Type (2025-2032) & (USD/MT)
Table 119. Global Anti-VEGF Therapeutic Sales (K MT) Forecast by Application (2025-2032)
Table 120. Global Anti-VEGF Therapeutic Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Anti-VEGF Therapeutic
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Anti-VEGF Therapeutic Market Size (M USD), 2019-2032
Figure 5. Global Anti-VEGF Therapeutic Market Size (M USD) (2019-2032)
Figure 6. Global Anti-VEGF Therapeutic Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Anti-VEGF Therapeutic Market Size by Country (M USD)
Figure 11. Anti-VEGF Therapeutic Sales Share by Manufacturers in 2023
Figure 12. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers in 2023
Figure 13. Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Anti-VEGF Therapeutic Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Anti-VEGF Therapeutic Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Anti-VEGF Therapeutic Market Share by Type
Figure 18. Sales Market Share of Anti-VEGF Therapeutic by Type (2019-2024)
Figure 19. Sales Market Share of Anti-VEGF Therapeutic by Type in 2023
Figure 20. Market Size Share of Anti-VEGF Therapeutic by Type (2019-2024)
Figure 21. Market Size Market Share of Anti-VEGF Therapeutic by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Anti-VEGF Therapeutic Market Share by Application
Figure 24. Global Anti-VEGF Therapeutic Sales Market Share by Application (2019-2024)
Figure 25. Global Anti-VEGF Therapeutic Sales Market Share by Application in 2023
Figure 26. Global Anti-VEGF Therapeutic Market Share by Application (2019-2024)
Figure 27. Global Anti-VEGF Therapeutic Market Share by Application in 2023
Figure 28. Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
Figure 29. Global Anti-VEGF Therapeutic Sales Market Share by Region (2019-2024)
Figure 30. North America Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 32. U.S. Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Anti-VEGF Therapeutic Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Anti-VEGF Therapeutic Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 37. Germany Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Anti-VEGF Therapeutic Sales Market Share by Region in 2023
Figure 44. China Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 50. South America Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 51. Brazil Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Anti-VEGF Therapeutic Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Anti-VEGF Therapeutic Production Market Share by Region (2019-2024)
Figure 62. North America Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 65. China Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Anti-VEGF Therapeutic Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Anti-VEGF Therapeutic Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Anti-VEGF Therapeutic Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Anti-VEGF Therapeutic Market Share Forecast by Type (2025-2032)
Figure 70. Global Anti-VEGF Therapeutic Sales Forecast by Application (2025-2032)
Figure 71. Global Anti-VEGF Therapeutic Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Anti-VEGF Therapeutic
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Anti-VEGF Therapeutic Market Size (M USD), 2019-2032
Figure 5. Global Anti-VEGF Therapeutic Market Size (M USD) (2019-2032)
Figure 6. Global Anti-VEGF Therapeutic Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Anti-VEGF Therapeutic Market Size by Country (M USD)
Figure 11. Anti-VEGF Therapeutic Sales Share by Manufacturers in 2023
Figure 12. Global Anti-VEGF Therapeutic Revenue Share by Manufacturers in 2023
Figure 13. Anti-VEGF Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Anti-VEGF Therapeutic Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Anti-VEGF Therapeutic Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Anti-VEGF Therapeutic Market Share by Type
Figure 18. Sales Market Share of Anti-VEGF Therapeutic by Type (2019-2024)
Figure 19. Sales Market Share of Anti-VEGF Therapeutic by Type in 2023
Figure 20. Market Size Share of Anti-VEGF Therapeutic by Type (2019-2024)
Figure 21. Market Size Market Share of Anti-VEGF Therapeutic by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Anti-VEGF Therapeutic Market Share by Application
Figure 24. Global Anti-VEGF Therapeutic Sales Market Share by Application (2019-2024)
Figure 25. Global Anti-VEGF Therapeutic Sales Market Share by Application in 2023
Figure 26. Global Anti-VEGF Therapeutic Market Share by Application (2019-2024)
Figure 27. Global Anti-VEGF Therapeutic Market Share by Application in 2023
Figure 28. Global Anti-VEGF Therapeutic Sales Growth Rate by Application (2019-2024)
Figure 29. Global Anti-VEGF Therapeutic Sales Market Share by Region (2019-2024)
Figure 30. North America Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 32. U.S. Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Anti-VEGF Therapeutic Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Anti-VEGF Therapeutic Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 37. Germany Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Anti-VEGF Therapeutic Sales Market Share by Region in 2023
Figure 44. China Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 50. South America Anti-VEGF Therapeutic Sales Market Share by Country in 2023
Figure 51. Brazil Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Anti-VEGF Therapeutic Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Anti-VEGF Therapeutic Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Anti-VEGF Therapeutic Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Anti-VEGF Therapeutic Production Market Share by Region (2019-2024)
Figure 62. North America Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 65. China Anti-VEGF Therapeutic Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Anti-VEGF Therapeutic Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Anti-VEGF Therapeutic Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Anti-VEGF Therapeutic Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Anti-VEGF Therapeutic Market Share Forecast by Type (2025-2032)
Figure 70. Global Anti-VEGF Therapeutic Sales Forecast by Application (2025-2032)
Figure 71. Global Anti-VEGF Therapeutic Market Share Forecast by Application (2025-2032)
